Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.49), versus ($0.51) reported last year. Revenue for the quarter came in at $10.43 million, versus $7.47 million reported last year.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Associated Banc-Corp (ASB) Tops Q1 EPS by 3c
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY24 Revenue Guidance